Tango Therapeutics, Inc.
TNGX
株式のランク
#4533
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
株価
$27.18
最終同期: 2026-07-31
時価総額
$3.38B
変化（1日）
-1.41%
変化（1年）
197.05%
国
US
取引 Tango Therapeutics, Inc. (TNGX)
カテゴリー
Healthcare
Tango Therapeutics, Inc.（TNGX）の営業利益率
October 2026 時点の営業利益率 TTM: -253.38%
Tango Therapeutics, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は -253.38% です。2023 年末時点では -312.57% でした。
Tango Therapeutics, Inc. の営業利益率の履歴（2019 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | -253.38% | -26.79% |
| 2024 | -346.09% | 10.72% |
| 2023 | -312.57% | -30.04% |
| 2022 | -446.79% | 184.42% |
| 2021 | -157.09% | -76.96% |
| 2020 | -681.82% | 1,008.47% |
| 2019 | -61.51% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -100.15% |
US
|
|
| -149.01% | -99.41% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.11% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。